Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model

BACKGROUND: The short-term efficacy of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD) has been demonstrated across several phase 3 trials, while the ADPKD Outcomes Model (ADPKD-OM) represents a validated approach to predict natural disease progression over a lifetime...

Descripción completa

Detalles Bibliográficos
Autores principales: Bennett, Hayley, McEwan, Phil, Hamilton, Karina, O’Reilly, Karl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480528/
https://www.ncbi.nlm.nih.gov/pubmed/31014270
http://dx.doi.org/10.1186/s12882-019-1290-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480528/
https://www.ncbi.nlm.nih.gov/pubmed/31014270
http://dx.doi.org/10.1186/s12882-019-1290-5

Ejemplares similares